The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-09 and is reviewed periodically as new material appears.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== Role in the immune system === Because the epithelium is often under external stress and is somewhat delicate, the lamina propria hosts many immune cells. In the intestinal tract the immune system must have tolerance to the normal intestinal flora, yet respond to pathogenic microorganisms. Imbalance of this causes inflammation diseases such as inflammatory bowel disease. The lamina propria’s richness in macrophages and lymphoid cells makes it a key place for immune responses to occur. It forms part of the barrier that protects internal tissues from external pathogenic microorganisms, especially from the gastrointestinal tract.
== Causes == The "a calorie is a calorie" model of obesity posits a combination of excessive food energy intake and a lack of physical activity as the cause of most cases of obesity. A limited number of cases are due primarily to genetics, medical reasons, or psychiatric illness. The satiety value shows that the feeling of satiety per calorie varies between food types. Increasing rates of obesity at a societal level are felt to be due to an easily accessible and palatable diet, increased reliance on cars, and mechanized manufacturing. Some other factors have been proposed as causes towards rising rates of obesity worldwide, including insufficient sleep, endocrine disruptors, increased usage of certain medications (such as atypical antipsychotics), increases in ambient temperature, decreased rates of smoking, demographic changes, increasing maternal age of first-time mothers, changes to epigenetic regulation from the environment, increased phenotypic variance via assortative mating, social pressure to diet, among others. According to one study in 2006, factors like these may play as big of a role as excessive food energy intake and a lack of physical activity; however, the relative magnitudes of the effects of any proposed cause of obesity is varied and uncertain, as there is a general need for randomized controlled trials on humans before definitive statement can be made.
=== Acting female viceregal representatives === This list includes women appointed as viceregal representatives in an acting capacity, wherein they assumed a vacated office on a temporary basis under the terms of a dormant commission.
=== EC 2.5: alkyl and aryl transferases === EC 2.5 relates to enzymes that transfer alkyl or aryl groups, but does not include methyl groups. This is in contrast to functional groups that become alkyl groups when transferred, as those are included in EC 2.3. EC 2.5 currently only possesses one sub-class: Alkyl and aryl transferases. Cysteine synthase, for example, catalyzes the formation of acetic acids and cysteine from O3-acetyl-L-serine and hydrogen sulfide: O3-acetyl-L-serine + H2S
Sources: en.wikipedia.org
== N == NAA – Neutron activation analysis ND – Neutron diffraction NDP – Neutron depth profiling NEXAFS – Near edge X-ray absorption fine structure NIS – Nuclear inelastic scattering/absorption NMR – Nuclear magnetic resonance spectroscopy NOESY – Nuclear Overhauser effect spectroscopy NRA – Nuclear reaction analysis NSOM – Near-field optical microscopy
== Packaging machines == A choice of packaging machinery requires consideration of technical capabilities, labor requirements, worker safety, maintainability, serviceability, reliability, ability to integrate into the packaging line, capital cost, floorspace, flexibility (change-over, materials, etc.), energy usage, quality of outgoing packages, qualifications (for food, pharmaceuticals, etc.), throughput, efficiency, productivity, and ergonomics, at a minimum. Packaging machines may be of the following general types:
India's population was 361 million in 1951. It grew to approximately 1.464 billion in 2025, surpassing China's population in 2021. 1,210,193,422 residents were reported in the 2011 provisional census report. The median age was 28.7 in 2020. Medical advances made in the last 50 years as well as increased agricultural productivity brought about by the "Green Revolution" have caused India's population to grow rapidly, though India's decennial rates of growth are decreasing: its population grew by 17.64% from 2001 to 2011, compared to 21.54% growth in the previous decade (1991–2001). The first post-colonial census, conducted in 1951, counted 361 million people. The life expectancy at birth has increased from 49.7 years in 1970–1975 to 72.0 years in 2023. The under-five mortality rate for the country was 113 per 1,000 live births in 1994, and had declined to 41.1 per 1,000 live births by 2018. The 2011 census reported a human sex ratio of 940 females per 1,000 males. Female infanticide in India, and lately female foeticide, have created lopsided gender ratios; the number of missing women in the country quadrupled from 15 million to 63 million during the period 1964–2014, faster than the population growth during the same period. According to an Indian government study, an additional 21 million girls are unwanted and do not receive adequate care. Despite a government ban on sex-selective foeticide, the practice persists. Migration from rural to urban areas has been an important dynamic in India's recent history.
Sources: en.wikipedia.org
The new tools of molecular biology changed the study of bird systematics, which changed from being based on phenotype to the underlying genotype. The use of techniques such as DNA–DNA hybridization to study evolutionary relationships was pioneered by Charles Sibley and Jon Edward Ahlquist, resulting in what is called the Sibley–Ahlquist taxonomy. These early techniques have been replaced by newer ones based on mitochondrial DNA sequences and molecular phylogenetics approaches that make use of computational procedures for sequence alignment, construction of phylogenetic trees, and calibration of molecular clocks to infer evolutionary relationships. Molecular techniques are also widely used in studies of avian population biology and ecology.
Diabetes burden and access to care vary widely between and within countries. Between 1990 and 2022, diabetes prevalence rose faster in low and middle income countries than in high-income countries. In 2022, more than half of adults aged 30 and over with diabetes were not taking medication for it, and treatment coverage was lowest in low and middle income countries. A pooled analysis of 1,108 population-based studies estimated that in most countries, especially low and middle income ones, treatment had not increased enough to keep pace with rising prevalence, and that the gap in treatment coverage between the countries widened from 56 percentage points in women and 43 in men in 1990 to 78 and 71 respectively in 2022. WHO reported in 2021 that essential diabetes medicines were available in only about half of facilities in low and lower middle income countries, compared to about 80% of facilities globally. The International Diabetes Federation estimated that 252 million adults aged 20–79 were unaware they had diabetes in 2024. Risk also differs between ethnic groups. South Asian people tend to develop type 2 diabetes earlier in life and often at a normal body mass index. In a study of British Pakistani and British Bangladeshi participants, those with a high genetic risk of both insulin deficiency and unfavourable fat distribution were diagnosed about 8 years earlier, at a BMI about 3 kg/m² lower, than those at low genetic risk. Disparities are also documented for Indigenous peoples.
The green neon tetra (P. simulans) and black neon tetra (Hyphessobrycon herbertaxelrodi) are distinct species—the latter belongs to a different genus—and not color varieties. The cardinal tetra (P. axelrodi) is also a similar species, but its greater extent of red coloring distinguishes it from the neon tetra. The name Hyphessobrycon innesi is an obsolete synonym for P. innesi.
=== Bankruptcy and sale to SPB Hospitality === On March 3, 2020, CraftWorks filed for Chapter 11 bankruptcy reorganization. At the same time, the company entered into an agreement with affiliates of Fortress Credit Co. LLC, its senior lenders, to sell the company for at least $138 million, plus the assumption of certain liabilities, CraftWorks said in a news release. However, Fortress Credit later withdrew a $23 million loan for continuing operations; it then agreed to fund $6 million to finance continuing operations, and on April 1, 2020, CraftWorks terminated nearly all 18,000 of their employees and terminated health care benefits as of March 31, 2020.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.